

Global Autologous CAR-T Cell Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031

<https://marketpublishers.com/r/G063DCC5D5A1EN.html>

Date: September 2025

Pages: 89

Price: US\$ 3,132.00 (Single User License)

ID: G063DCC5D5A1EN

Abstracts

According to our (Global Info Research) latest study, the global Autologous CAR-T Cell Therapy market size was valued at US\$ 4566 million in 2024 and is forecast to a readjusted size of USD 17680 million by 2031 with a CAGR of 21.6% during review period.

CAR-T cell therapy is a novel immunotherapy method, abbreviated as chimeric antigen receptor T cells. Autologous CAR-T cell therapy uses the patient's own T cells, which are genetically engineered to express a specific receptor, thereby enhancing their ability to target tumor cells.

Cell immunotherapy techniques, represented by chimeric antigen receptor T-cell immunotherapy (CAR-T therapy), express CAR fusion proteins on the surface of T cells through genetic engineering technology. The CAR extracellular antigen recognition region (one of the components of CAR cells, responsible for recognizing tumor cell surface antigens) can specifically recognize tumor antigens and transmit signals into cells to activate T cells, achieving proliferation and targeted killing of tumor cells. CAR-T therapy has shown breakthrough efficacy and enormous potential for development and market prospects for cancer patients who are unable to cope with traditional treatments. CAR-T cells are divided into autologous and allogeneic CAR-T cells. At present, CAR-T therapy mainly uses autologous CAR-T cells.

In recent years, the progress of autologous CAR-T cell therapy in hematological tumors has inspired scientists to extend this technology to the treatment of solid tumors. However, the current progress in the treatment of solid tumors is relatively slow. But in the future, with the discovery of more targets and the development of clinical trials, solid

tumors are expected to become the main treatment area for CAR-T. At present, JW (Cayman) Therapeutics is laying out more innovative products to officially enter the field of cell therapy for solid tumors.

This report is a detailed and comprehensive analysis for global Autologous CAR-T Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Autologous CAR-T Cell Therapy market size and forecasts, in consumption value (\$ Million), 2020-2031

Global Autologous CAR-T Cell Therapy market size and forecasts by region and country, in consumption value (\$ Million), 2020-2031

Global Autologous CAR-T Cell Therapy market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2020-2031

Global Autologous CAR-T Cell Therapy market shares of main players, in revenue (\$ Million), 2020-2025

The Primary Objectives in This Report Are:

- To determine the size of the total market opportunity of global and key countries
- To assess the growth potential for Autologous CAR-T Cell Therapy
- To forecast future growth in each product and end-use market
- To assess competitive factors affecting the marketplace

This report profiles key players in the global Autologous CAR-T Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Gilead (Kite Pharma), Bristol Myers Squibb, Fosun Kite Biotechnology, JW Therapeutics, Bluebird Bio, IASO Bio, Juventas Cell Therapy, Legend Biotech, CARsge, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Autologous CAR-T Cell Therapy market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Target: CD19

Target: BCMA

Market segment by Application

Hematological Tumors

Solid Tumor

Market segment by players, this report covers

Novartis

Gilead (Kite Pharma)

Bristol Myers Squibb

Fosun Kite Biotechnology

JW Therapeutics

Bluebird Bio

IASO Bio

Juventas Cell Therapy

Legend Biotech

CARsge

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Autologous CAR-T Cell Therapy product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Autologous CAR-T Cell Therapy, with revenue, gross margin, and global market share of Autologous CAR-T Cell Therapy from 2020 to 2025.

Chapter 3, the Autologous CAR-T Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025. and Autologous CAR-T Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Autologous CAR-T Cell Therapy.

Chapter 13, to describe Autologous CAR-T Cell Therapy research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Autologous CAR-T Cell Therapy by Type

1.3.1 Overview: Global Autologous CAR-T Cell Therapy Market Size by Type: 2020 Versus 2024 Versus 2031

1.3.2 Global Autologous CAR-T Cell Therapy Consumption Value Market Share by Type in 2024

1.3.3 Target: CD19

1.3.4 Target: BCMA

1.4 Global Autologous CAR-T Cell Therapy Market by Application

1.4.1 Overview: Global Autologous CAR-T Cell Therapy Market Size by Application: 2020 Versus 2024 Versus 2031

1.4.2 Hematological Tumors

1.4.3 Solid Tumor

1.5 Global Autologous CAR-T Cell Therapy Market Size & Forecast

1.6 Global Autologous CAR-T Cell Therapy Market Size and Forecast by Region

1.6.1 Global Autologous CAR-T Cell Therapy Market Size by Region: 2020 VS 2024 VS 2031

1.6.2 Global Autologous CAR-T Cell Therapy Market Size by Region, (2020-2031)

1.6.3 North America Autologous CAR-T Cell Therapy Market Size and Prospect (2020-2031)

1.6.4 Europe Autologous CAR-T Cell Therapy Market Size and Prospect (2020-2031)

1.6.5 Asia-Pacific Autologous CAR-T Cell Therapy Market Size and Prospect (2020-2031)

1.6.6 South America Autologous CAR-T Cell Therapy Market Size and Prospect (2020-2031)

1.6.7 Middle East & Africa Autologous CAR-T Cell Therapy Market Size and Prospect (2020-2031)

2 COMPANY PROFILES

2.1 Novartis

2.1.1 Novartis Details

2.1.2 Novartis Major Business

2.1.3 Novartis Autologous CAR-T Cell Therapy Product and Solutions

2.1.4 Novartis Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.1.5 Novartis Recent Developments and Future Plans

2.2 Gilead (Kite Pharma)

2.2.1 Gilead (Kite Pharma) Details

2.2.2 Gilead (Kite Pharma) Major Business

2.2.3 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Product and Solutions

2.2.4 Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.2.5 Gilead (Kite Pharma) Recent Developments and Future Plans

2.3 Bristol Myers Squibb

2.3.1 Bristol Myers Squibb Details

2.3.2 Bristol Myers Squibb Major Business

2.3.3 Bristol Myers Squibb Autologous CAR-T Cell Therapy Product and Solutions

2.3.4 Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.3.5 Bristol Myers Squibb Recent Developments and Future Plans

2.4 Fosun Kite Biotechnology

2.4.1 Fosun Kite Biotechnology Details

2.4.2 Fosun Kite Biotechnology Major Business

2.4.3 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Product and Solutions

2.4.4 Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.4.5 Fosun Kite Biotechnology Recent Developments and Future Plans

2.5 JW Therapeutics

2.5.1 JW Therapeutics Details

2.5.2 JW Therapeutics Major Business

2.5.3 JW Therapeutics Autologous CAR-T Cell Therapy Product and Solutions

2.5.4 JW Therapeutics Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.5.5 JW Therapeutics Recent Developments and Future Plans

2.6 Bluebird Bio

2.6.1 Bluebird Bio Details

2.6.2 Bluebird Bio Major Business

2.6.3 Bluebird Bio Autologous CAR-T Cell Therapy Product and Solutions

2.6.4 Bluebird Bio Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.6.5 Bluebird Bio Recent Developments and Future Plans

2.7 IASO Bio

2.7.1 IASO Bio Details

2.7.2 IASO Bio Major Business

2.7.3 IASO Bio Autologous CAR-T Cell Therapy Product and Solutions

2.7.4 IASO Bio Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.7.5 IASO Bio Recent Developments and Future Plans

2.8 Juventas Cell Therapy

2.8.1 Juventas Cell Therapy Details

2.8.2 Juventas Cell Therapy Major Business

2.8.3 Juventas Cell Therapy Autologous CAR-T Cell Therapy Product and Solutions

2.8.4 Juventas Cell Therapy Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.8.5 Juventas Cell Therapy Recent Developments and Future Plans

2.9 Legend Biotech

2.9.1 Legend Biotech Details

2.9.2 Legend Biotech Major Business

2.9.3 Legend Biotech Autologous CAR-T Cell Therapy Product and Solutions

2.9.4 Legend Biotech Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.9.5 Legend Biotech Recent Developments and Future Plans

2.10 CARsge

2.10.1 CARsge Details

2.10.2 CARsge Major Business

2.10.3 CARsge Autologous CAR-T Cell Therapy Product and Solutions

2.10.4 CARsge Autologous CAR-T Cell Therapy Revenue, Gross Margin and Market Share (2020-2025)

2.10.5 CARsge Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

3.1 Global Autologous CAR-T Cell Therapy Revenue and Share by Players (2020-2025)

3.2 Market Share Analysis (2024)

3.2.1 Market Share of Autologous CAR-T Cell Therapy by Company Revenue

3.2.2 Top 3 Autologous CAR-T Cell Therapy Players Market Share in 2024

3.2.3 Top 6 Autologous CAR-T Cell Therapy Players Market Share in 2024

3.3 Autologous CAR-T Cell Therapy Market: Overall Company Footprint Analysis

3.3.1 Autologous CAR-T Cell Therapy Market: Region Footprint

3.3.2 Autologous CAR-T Cell Therapy Market: Company Product Type Footprint

- 3.3.3 Autologous CAR-T Cell Therapy Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global Autologous CAR-T Cell Therapy Consumption Value and Market Share by Type (2020-2025)
- 4.2 Global Autologous CAR-T Cell Therapy Market Forecast by Type (2026-2031)

5 MARKET SIZE SEGMENT BY APPLICATION

- 5.1 Global Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2025)
- 5.2 Global Autologous CAR-T Cell Therapy Market Forecast by Application (2026-2031)

6 NORTH AMERICA

- 6.1 North America Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2031)
- 6.2 North America Autologous CAR-T Cell Therapy Market Size by Application (2020-2031)
- 6.3 North America Autologous CAR-T Cell Therapy Market Size by Country
 - 6.3.1 North America Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2031)
 - 6.3.2 United States Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)
 - 6.3.3 Canada Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)
 - 6.3.4 Mexico Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

7 EUROPE

- 7.1 Europe Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2031)
- 7.2 Europe Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2031)
- 7.3 Europe Autologous CAR-T Cell Therapy Market Size by Country
 - 7.3.1 Europe Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2031)
 - 7.3.2 Germany Autologous CAR-T Cell Therapy Market Size and Forecast

(2020-2031)

7.3.3 France Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

7.3.4 United Kingdom Autologous CAR-T Cell Therapy Market Size and Forecast
(2020-2031)

7.3.5 Russia Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

7.3.6 Italy Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

8 ASIA-PACIFIC

8.1 Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Type
(2020-2031)

8.2 Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Application
(2020-2031)

8.3 Asia-Pacific Autologous CAR-T Cell Therapy Market Size by Region

8.3.1 Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Region
(2020-2031)

8.3.2 China Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

8.3.3 Japan Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

8.3.4 South Korea Autologous CAR-T Cell Therapy Market Size and Forecast
(2020-2031)

8.3.5 India Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

8.3.6 Southeast Asia Autologous CAR-T Cell Therapy Market Size and Forecast
(2020-2031)

8.3.7 Australia Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

9 SOUTH AMERICA

9.1 South America Autologous CAR-T Cell Therapy Consumption Value by Type
(2020-2031)

9.2 South America Autologous CAR-T Cell Therapy Consumption Value by Application
(2020-2031)

9.3 South America Autologous CAR-T Cell Therapy Market Size by Country

9.3.1 South America Autologous CAR-T Cell Therapy Consumption Value by Country
(2020-2031)

9.3.2 Brazil Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

9.3.3 Argentina Autologous CAR-T Cell Therapy Market Size and Forecast
(2020-2031)

10 MIDDLE EAST & AFRICA

10.1 Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2031)

10.2 Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2031)

10.3 Middle East & Africa Autologous CAR-T Cell Therapy Market Size by Country

10.3.1 Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2031)

10.3.2 Turkey Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

10.3.3 Saudi Arabia Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

10.3.4 UAE Autologous CAR-T Cell Therapy Market Size and Forecast (2020-2031)

11 MARKET DYNAMICS

11.1 Autologous CAR-T Cell Therapy Market Drivers

11.2 Autologous CAR-T Cell Therapy Market Restraints

11.3 Autologous CAR-T Cell Therapy Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 Autologous CAR-T Cell Therapy Industry Chain

12.2 Autologous CAR-T Cell Therapy Upstream Analysis

12.3 Autologous CAR-T Cell Therapy Midstream Analysis

12.4 Autologous CAR-T Cell Therapy Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global Autologous CAR-T Cell Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Table 2. Global Autologous CAR-T Cell Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Table 3. Global Autologous CAR-T Cell Therapy Consumption Value by Region (2020-2025) & (USD Million)

Table 4. Global Autologous CAR-T Cell Therapy Consumption Value by Region (2026-2031) & (USD Million)

Table 5. Novartis Company Information, Head Office, and Major Competitors

Table 6. Novartis Major Business

Table 7. Novartis Autologous CAR-T Cell Therapy Product and Solutions

Table 8. Novartis Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 9. Novartis Recent Developments and Future Plans

Table 10. Gilead (Kite Pharma) Company Information, Head Office, and Major Competitors

Table 11. Gilead (Kite Pharma) Major Business

Table 12. Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Product and Solutions

Table 13. Gilead (Kite Pharma) Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 14. Gilead (Kite Pharma) Recent Developments and Future Plans

Table 15. Bristol Myers Squibb Company Information, Head Office, and Major Competitors

Table 16. Bristol Myers Squibb Major Business

Table 17. Bristol Myers Squibb Autologous CAR-T Cell Therapy Product and Solutions

Table 18. Bristol Myers Squibb Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 19. Fosun Kite Biotechnology Company Information, Head Office, and Major Competitors

Table 20. Fosun Kite Biotechnology Major Business

Table 21. Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Product and Solutions

Table 22. Fosun Kite Biotechnology Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 23. Fosun Kite Biotechnology Recent Developments and Future Plans

Table 24. JW Therapeutics Company Information, Head Office, and Major Competitors

Table 25. JW Therapeutics Major Business

Table 26. JW Therapeutics Autologous CAR-T Cell Therapy Product and Solutions

Table 27. JW Therapeutics Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 28. JW Therapeutics Recent Developments and Future Plans

Table 29. Bluebird Bio Company Information, Head Office, and Major Competitors

Table 30. Bluebird Bio Major Business

Table 31. Bluebird Bio Autologous CAR-T Cell Therapy Product and Solutions

Table 32. Bluebird Bio Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 33. Bluebird Bio Recent Developments and Future Plans

Table 34. IASO Bio Company Information, Head Office, and Major Competitors

Table 35. IASO Bio Major Business

Table 36. IASO Bio Autologous CAR-T Cell Therapy Product and Solutions

Table 37. IASO Bio Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 38. IASO Bio Recent Developments and Future Plans

Table 39. Juventas Cell Therapy Company Information, Head Office, and Major Competitors

Table 40. Juventas Cell Therapy Major Business

Table 41. Juventas Cell Therapy Autologous CAR-T Cell Therapy Product and Solutions

Table 42. Juventas Cell Therapy Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 43. Juventas Cell Therapy Recent Developments and Future Plans

Table 44. Legend Biotech Company Information, Head Office, and Major Competitors

Table 45. Legend Biotech Major Business

Table 46. Legend Biotech Autologous CAR-T Cell Therapy Product and Solutions

Table 47. Legend Biotech Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 48. Legend Biotech Recent Developments and Future Plans

Table 49. CARsge Company Information, Head Office, and Major Competitors

Table 50. CARsge Major Business

Table 51. CARsge Autologous CAR-T Cell Therapy Product and Solutions

Table 52. CARsge Autologous CAR-T Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2020-2025)

Table 53. CARsge Recent Developments and Future Plans

Table 54. Global Autologous CAR-T Cell Therapy Revenue (USD Million) by Players

(2020-2025)

Table 55. Global Autologous CAR-T Cell Therapy Revenue Share by Players

(2020-2025)

Table 56. Breakdown of Autologous CAR-T Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)

Table 57. Market Position of Players in Autologous CAR-T Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024

Table 58. Head Office of Key Autologous CAR-T Cell Therapy Players

Table 59. Autologous CAR-T Cell Therapy Market: Company Product Type Footprint

Table 60. Autologous CAR-T Cell Therapy Market: Company Product Application Footprint

Table 61. Autologous CAR-T Cell Therapy New Market Entrants and Barriers to Market Entry

Table 62. Autologous CAR-T Cell Therapy Mergers, Acquisition, Agreements, and Collaborations

Table 63. Global Autologous CAR-T Cell Therapy Consumption Value (USD Million) by Type (2020-2025)

Table 64. Global Autologous CAR-T Cell Therapy Consumption Value Share by Type (2020-2025)

Table 65. Global Autologous CAR-T Cell Therapy Consumption Value Forecast by Type (2026-2031)

Table 66. Global Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2025)

Table 67. Global Autologous CAR-T Cell Therapy Consumption Value Forecast by Application (2026-2031)

Table 68. North America Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2025) & (USD Million)

Table 69. North America Autologous CAR-T Cell Therapy Consumption Value by Type (2026-2031) & (USD Million)

Table 70. North America Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2025) & (USD Million)

Table 71. North America Autologous CAR-T Cell Therapy Consumption Value by Application (2026-2031) & (USD Million)

Table 72. North America Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2025) & (USD Million)

Table 73. North America Autologous CAR-T Cell Therapy Consumption Value by Country (2026-2031) & (USD Million)

Table 74. Europe Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2025) & (USD Million)

Table 75. Europe Autologous CAR-T Cell Therapy Consumption Value by Type (2026-2031) & (USD Million)

Table 76. Europe Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2025) & (USD Million)

Table 77. Europe Autologous CAR-T Cell Therapy Consumption Value by Application (2026-2031) & (USD Million)

Table 78. Europe Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2025) & (USD Million)

Table 79. Europe Autologous CAR-T Cell Therapy Consumption Value by Country (2026-2031) & (USD Million)

Table 80. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2025) & (USD Million)

Table 81. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Type (2026-2031) & (USD Million)

Table 82. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2025) & (USD Million)

Table 83. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Application (2026-2031) & (USD Million)

Table 84. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Region (2020-2025) & (USD Million)

Table 85. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value by Region (2026-2031) & (USD Million)

Table 86. South America Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2025) & (USD Million)

Table 87. South America Autologous CAR-T Cell Therapy Consumption Value by Type (2026-2031) & (USD Million)

Table 88. South America Autologous CAR-T Cell Therapy Consumption Value by Application (2020-2025) & (USD Million)

Table 89. South America Autologous CAR-T Cell Therapy Consumption Value by Application (2026-2031) & (USD Million)

Table 90. South America Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2025) & (USD Million)

Table 91. South America Autologous CAR-T Cell Therapy Consumption Value by Country (2026-2031) & (USD Million)

Table 92. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Type (2020-2025) & (USD Million)

Table 93. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Type (2026-2031) & (USD Million)

Table 94. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by

Application (2020-2025) & (USD Million)

Table 95. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Application (2026-2031) & (USD Million)

Table 96. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Country (2020-2025) & (USD Million)

Table 97. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value by Country (2026-2031) & (USD Million)

Table 98. Global Key Players of Autologous CAR-T Cell Therapy Upstream (Raw Materials)

Table 99. Global Autologous CAR-T Cell Therapy Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. Autologous CAR-T Cell Therapy Picture

Figure 2. Global Autologous CAR-T Cell Therapy Consumption Value by Type, (USD Million), 2020 & 2024 & 2031

Figure 3. Global Autologous CAR-T Cell Therapy Consumption Value Market Share by Type in 2024

Figure 4. Target: CD19

Figure 5. Target: BCMA

Figure 6. Global Autologous CAR-T Cell Therapy Consumption Value by Application, (USD Million), 2020 & 2024 & 2031

Figure 7. Autologous CAR-T Cell Therapy Consumption Value Market Share by Application in 2024

Figure 8. Hematological Tumors Picture

Figure 9. Solid Tumor Picture

Figure 10. Global Autologous CAR-T Cell Therapy Consumption Value, (USD Million): 2020 & 2024 & 2031

Figure 11. Global Autologous CAR-T Cell Therapy Consumption Value and Forecast (2020-2031) & (USD Million)

Figure 12. Global Market Autologous CAR-T Cell Therapy Consumption Value (USD Million) Comparison by Region (2020 VS 2024 VS 2031)

Figure 13. Global Autologous CAR-T Cell Therapy Consumption Value Market Share by Region (2020-2031)

Figure 14. Global Autologous CAR-T Cell Therapy Consumption Value Market Share by Region in 2024

Figure 15. North America Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 16. Europe Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 17. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 18. South America Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 19. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 20. Company Three Recent Developments and Future Plans

Figure 21. Global Autologous CAR-T Cell Therapy Revenue Share by Players in 2024

Figure 22. Autologous CAR-T Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024

Figure 23. Market Share of Autologous CAR-T Cell Therapy by Player Revenue in 2024

Figure 24. Top 3 Autologous CAR-T Cell Therapy Players Market Share in 2024

Figure 25. Top 6 Autologous CAR-T Cell Therapy Players Market Share in 2024

Figure 26. Global Autologous CAR-T Cell Therapy Consumption Value Share by Type (2020-2025)

Figure 27. Global Autologous CAR-T Cell Therapy Market Share Forecast by Type (2026-2031)

Figure 28. Global Autologous CAR-T Cell Therapy Consumption Value Share by Application (2020-2025)

Figure 29. Global Autologous CAR-T Cell Therapy Market Share Forecast by Application (2026-2031)

Figure 30. North America Autologous CAR-T Cell Therapy Consumption Value Market Share by Type (2020-2031)

Figure 31. North America Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2031)

Figure 32. North America Autologous CAR-T Cell Therapy Consumption Value Market Share by Country (2020-2031)

Figure 33. United States Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 34. Canada Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 35. Mexico Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 36. Europe Autologous CAR-T Cell Therapy Consumption Value Market Share by Type (2020-2031)

Figure 37. Europe Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2031)

Figure 38. Europe Autologous CAR-T Cell Therapy Consumption Value Market Share by Country (2020-2031)

Figure 39. Germany Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 40. France Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 41. United Kingdom Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 42. Russia Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 43. Italy Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 44. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value Market Share by Type (2020-2031)

Figure 45. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2031)

Figure 46. Asia-Pacific Autologous CAR-T Cell Therapy Consumption Value Market Share by Region (2020-2031)

Figure 47. China Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 48. Japan Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 49. South Korea Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 50. India Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 51. Southeast Asia Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 52. Australia Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 53. South America Autologous CAR-T Cell Therapy Consumption Value Market Share by Type (2020-2031)

Figure 54. South America Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2031)

Figure 55. South America Autologous CAR-T Cell Therapy Consumption Value Market Share by Country (2020-2031)

Figure 56. Brazil Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 57. Argentina Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 58. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value Market Share by Type (2020-2031)

Figure 59. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value Market Share by Application (2020-2031)

Figure 60. Middle East & Africa Autologous CAR-T Cell Therapy Consumption Value Market Share by Country (2020-2031)

Figure 61. Turkey Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 62. Saudi Arabia Autologous CAR-T Cell Therapy Consumption Value

(2020-2031) & (USD Million)

Figure 63. UAE Autologous CAR-T Cell Therapy Consumption Value (2020-2031) & (USD Million)

Figure 64. Autologous CAR-T Cell Therapy Market Drivers

Figure 65. Autologous CAR-T Cell Therapy Market Restraints

Figure 66. Autologous CAR-T Cell Therapy Market Trends

Figure 67. Porters Five Forces Analysis

Figure 68. Autologous CAR-T Cell Therapy Industrial Chain

Figure 69. Methodology

Figure 70. Research Process and Data Source

I would like to order

Product name: Global Autologous CAR-T Cell Therapy Market 2025 by Company, Regions, Type and Application, Forecast to 2031

Product link: <https://marketpublishers.com/r/G063DCC5D5A1EN.html>

Price: US\$ 3,132.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G063DCC5D5A1EN.html>